Načítá se...
Daratumumab in untreated newly diagnosed multiple myeloma
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/refractory multiple myeloma both as monothe...
Uloženo v:
| Vydáno v: | Ther Adv Hematol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6928545/ https://ncbi.nlm.nih.gov/pubmed/31903177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719894871 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|